黄酮类化合物防治糖尿病微血管病变的研究进展

郭苏 ,  秦小江 ,  江雪露 ,  方梦薇 ,  满志 ,  孟欣 ,  郑志发 ,  赵良渊 ,  施熠炜 ,  侯晓敏

中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 752 -763.

PDF (7171KB)
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (6) : 752 -763. DOI: 10.12092/j.issn.1009-2501.2026.06.004

黄酮类化合物防治糖尿病微血管病变的研究进展

作者信息 +

Research progress on flavonoids in the prevention and treatment of diabetic microvascular complications

Author information +
文章历史 +
PDF (7342K)

摘要

糖尿病是一种以慢性高血糖为特征的常见代谢性疾病。长期高血糖可损伤全身微血管,包括视网膜、肾小球、神经营养血管及心肌微小冠状动脉等,临床表现为糖尿病视网膜病变(diabetic retinopathy,DR)、糖尿病肾病(diabetic kidney disease,DKD)、糖尿病神经病变(diabetic neuropathy,DN)和糖尿病心肌病变(diabetic cardiomyopathy,DCM)。这些并发症严重影响患者生活质量,甚至危及生命。糖尿病微血管病变的发病机制与高血糖诱导的代谢途径异常激活、氧化应激及炎症反应等密切相关,最终导致微血管内皮功能损伤、基底膜增厚和微循环障碍。黄酮类化合物作为一类广泛存在于植物中的天然产物,具有抗炎、抗氧化和保护血管内皮等多种生物活性,在防治糖尿病微血管病变方面展现出巨大潜力。本文综述了近年来黄酮类化合物在该领域的研究进展,并探讨了其在临床应用中的挑战和未来发展方向,以期为后续开发和应用提供参考。

Abstract

Diabetes mellitus is a common metabolic disease characterized by chronic hyperglycemia. Prolonged elevated blood glucose levels damage microvasculature throughout the body (including those in the retina, renal glomeruli, vasa nervorum, and intramyocardial small coronary arteries). This leads to clinical manifestations such as diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, and diabetic cardiomyopathy, all of which significantly impair the patient's quality of life and can even pose fatal risks. The pathogenesis of diabetic microvascular complications is closely associated with pathological changes induced by hyperglycemia, including the abnormal activation of multiple metabolic pathways, oxidative stress, and inflammatory responses, among other factors. These processes ultimately lead to pathological alterations, including microvascular endothelial dysfunction, basement membrane thickening, and microcirculatory disturbances. Flavonoids, a broad class of naturally occurring compounds ubiquitous in plants, possess a wide range of biological activities, such as anti-inflammatory, antioxidant, and endothelium-protective effects, which render them highly promising for preventing and treating diabetic microvascular complications. This review summarizes recent advances in the study of flavonoids for preventing and treating diabetic microvascular complications. Furthermore, it discusses the current challenges and future directions for the clinical use of flavonoids, aiming to provide a comprehensive reference for their continued development and applications.

关键词

黄酮类化合物 / 糖尿病 / 微血管病变

Key words

flavonoids / diabetes mellitus / microvascular complications

引用本文

引用格式 ▾
郭苏,秦小江,江雪露,方梦薇,满志,孟欣,郑志发,赵良渊,施熠炜,侯晓敏. 黄酮类化合物防治糖尿病微血管病变的研究进展[J]. 中国临床药理学与治疗学, 2026, 31(6): 752-763 DOI:10.12092/j.issn.1009-2501.2026.06.004

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

Roy B. Pathophysiological mechanisms of diabetes-induced macrovascular and microvascular complications: the role of oxidative stress[J].Med Sci, 2025, 13(3): 87.

[2]

Desoye G, Simmons D, van Poppel M. Identifying type 2 diabetes risk at birth: a new frontier for early prevention[J].Diabetes Care, 2025, 48(8): 1320-1322.

[3]

丁浚峰, 涂珺. 中药治疗糖尿病微血管病变的研究进展[J].中国实验方剂学杂志, 2023, 29(6): 260-267.

[4]

Hu X, Lv J, Zhao Y, et al. Important regulatory role of mitophagy in diabetic microvascular complications[J].J Transl Med, 2025, 23(1): 269.

[5]

何婉如, 张晓熙, 徐长玉, 等. 黄酮类化合物防治糖尿病及其并发症研究进展[J].浙江中医药大学学报, 2024, 48(2): 241-246.

[6]

Leonte D, Ungureanu D, Zaharia V.Flavones and related compounds: synthesis and biological activity[J].Molecules, 2023, 28(18): 6528.

[7]

Chen S, Wang X, Cheng Y, et al. A review of classification, biosynthesis, biological activities and potential applications of flavonoids[J].Molecules, 2023, 28(13): 4982.

[8]

Kumar S, Pandey AK.Chemistry and biological activities of flavonoids: an overview[J].Sci World J, 2013, 2013: 162750.

[9]

Agarawal K, Anant Kulkarni Y, Wairkar S. Nanoformulations of flavonoids for diabetes and microvascular diabetic complications[J].Drug Deliv Transl Res, 2023, 13(1): 18-36.

[10]

Hao B, Yang Z, Liu H, et al. Advances in flavonoid research: sources, biological activities, and developmental prospectives[J].Curr Issues Mol Biol, 2024, 46(4): 2884-2925.

[11]

Xiong Y, Knoedler S, Alfertshofer M, et al. Mechanisms and therapeutic opportunities in metabolic aberrations of diabetic wounds: a narrative review[J].Cell Death Dis, 2025, 16(1): 341.

[12]

Chen X, Xie N, Feng L, et al. Oxidative stress in diabetes mellitus and its complications: from pathophysiology to therapeutic strategies[J].Chin Med J, 2025, 138(1): 15-27.

[13]

Pan D, Xu L, Guo M.The role of protein kinase C in diabetic microvascular complications[J].Front Endocrinol, 2022, 13: 973058.

[14]

Qin P, He C, Ye P, et al. Pkcδ regulates the vascular biology in diabetic atherosclerosis[J].Cell Commun Signal, 2023, 21(1): 1-18.

[15]

Zhang Y, Zhang Z, Tu C, et al. Advanced glycation end products in disease development and potential interventions[J].Antioxidants, 2025, 14(4): 492.

[16]

Rojas A, Lindner C, Schneider I, et al. The RAGE axis: a relevant inflammatory hub in human diseases[J].Biomolecules, 2024, 14(4): 412.

[17]

Yamaguchi H, Nagai R. Insights from the fructose-derived product glucoselysine: revisiting the polyol pathway in diabetic complications[J].J Diabetes Investig, 2025, 16(4): 569-577.

[18]

Thorne CA, Grey AC, Lim JC, et al. The synergistic effects of polyol pathway-induced oxidative and osmotic stress in the aetiology of diabetic cataracts[J].Int J Mol Sci, 2024, 25(16): 9042.

[19]

An Y, Xu BT, Wan SR, et al. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction[J].Cardiovasc Diabetol, 2023, 22(1): 237.

[20]

Li Y, Liu Y, Liu S, et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies[J].Signal Transduct Target Ther, 2023, 8(1): 152.

[21]

Liu S, Liu J, Wang Y, et al. Oxidative stress: signaling pathways, biological functions, and disease[J].MedComm, 2025, 6(7): e70268.

[22]

Jia G, Bai H, Mather B, et al. Diabetic vasculopathy: molecular mechanisms and clinical insights[J].Int J Mol Sci, 2024, 25(2): 804.

[23]

Nashtahosseini Z, Eslami M, Paraandavaji E, et al. Cytokine signaling in diabetic neuropathy: a key player in peripheral nerve damage[J].Biomedicines, 2025, 13(3): 589.

[24]

Xue C, Chen K, Gao Z, et al. Common mechanisms underlying diabetic vascular complications: focus on the interaction of metabolic disorders, immuno-inflammation, and endothelial dysfunction[J].Cell Commun Signal, 2023, 21(1): 298.

[25]

Seo H, Park SJ, Song M. Diabetic retinopathy (DR): mechanisms, current therapies, and emerging strategies[J].Cells, 2025, 14(5): 376.

[26]

Muhammad T, Ikram M, Ullah R, et al. Hesperetin, a citrus flavonoid, attenuates LPS-induced neuroinflammation, apoptosis and memory impairments by modulating TLR4/NF-κB signaling[J].Nutrients, 2019, 11(3): 648.

[27]

Xue B, Wang Y.Naringenin upregulates GTPCH1/eNOS to ameliorate high glucose-induced retinal endothelial cell injury[J].Exp Ther Med, 2022, 23(6): 1-9.

[28]

Wu Y, Zhang Q, Zhang R.Kaempferol targets estrogen-related receptor α and suppresses the angiogenesis of human retinal endothelial cells under high glucose conditions[J].Exp Ther Med, 2017, 14(6): 5576-5582.

[29]

Gómez-Jiménez V, Burggraaf-Sánchez de Las Matas R, Ortega ÁL. Modulation of oxidative stress in diabetic retinopathy: therapeutic role of natural polyphenols[J].Antioxidants, 2025, 14(7): 875.

[30]

Yang Y, Zhou M, Liu H.Luteolin, an aryl hydrocarbon receptor antagonist, alleviates diabetic retinopathy by regulating the nlrp/Nox4 signalling pathway: experimental and molecular docking study[J].Physiol Int, 2021, 108(2): 211-222.

[31]

Matos AL, Bruno DF, Ambrósio AF, et al. The benefits of flavonoids in diabetic retinopathy[J].Nutrients, 2020, 12(10): 3169.

[32]

Lerner G. Investigation of diabetic kidney disease in the network for pancreatic organ donors with diabetes-kidney cohort[J].Kidney360, 2025, 6(1): 1-3.

[33]

Huang R, Zeng J, Yu X, et al. Luteolin alleviates diabetic nephropathy fibrosis involving AMPK/NLRP3/TGF-Β pathway[J].Diabetes Metab Syndr Obes, 2024, 17: 2855-2867.

[34]

Liu Y, Li Y, Xu L, et al. Quercetin attenuates podocyte apoptosis of diabetic nephropathy through targeting EGFR signaling[J].Front Pharmacol, 2021, 12: 792777.

[35]

Feng Q, Yang Y, Qiao Y, et al. Quercetin ameliorates diabetic kidney injury by inhibiting ferroptosis via activating Nrf2/HO-1 signaling pathway[J].Am J Chin Med, 2023, 51(4): 997-1018.

[36]

Hu Q, Qu C, Xiao X, et al. Flavonoids on diabetic nephropathy: advances and therapeutic opportunities[J].Chin Med, 2021, 16(1): 74.

[37]

Valle-Velázquez E, Zambrano-Vásquez OR, Cortés-Camacho F, et al. Naringenin - a potential nephroprotective agent for diabetic kidney disease: a comprehensive review of scientific evidence[J].Biomol Biomed, 2024, 24(6): 1441-1451.

[38]

Ma L, Wu F, Shao Q, et al. Baicalin alleviates oxidative stress and inflammation in diabetic nephropathy via Nrf2 and MAPK signaling pathway[J].Drug Des Devel Ther, 2021, 15: 3207-3221.

[39]

刘世林, 李安冬, 南征, 等. 糖尿病肾脏疾病足细胞自噬机制及中药干预研究进展[J].长春中医药大学学报, 2025, 41(5): 586-590.

[40]

Eid SA, Rumora AE, Beirowski B, et al. New perspectives in diabetic neuropathy[J].Neuron, 2023, 111(17): 2623-2641.

[41]

Zhang Q, Song W, Zhao B, et al. Quercetin attenuates diabetic peripheral neuropathy by correcting mitochondrial abnormality via activation of AMPK/PGC-1α pathway in vivo and in vitro[J].Front Neurosci, 2021, 15: 636172.

[42]

Song W, Li Y, Jia Y, et al. Quercetin alleviates diabetic peripheral neuropathy by regulating axon guidance factors and inhibiting the rho/ROCK pathway in vivo and in vitro[J].Diabetes Metab Syndr Obes, 2024, 17: 4339-4354.

[43]

Oh YS. Bioactive compounds and their neuroprotective effects in diabetic complications[J].Nutrients, 2016, 8(8): 472.

[44]

Weng L, Zhang F, Wang R, et al. A review on protective role of genistein against oxidative stress in diabetes and related complications[J].Chem Biol Interact, 2019, 310: 108665.

[45]

Khanna S, Kumar S, Sharma P, et al. Flavonoids regulating NLRP3 inflammasome: a promising approach in alleviating diabetic peripheral neuropathy[J].Inflammopharmacology, 2025, 33(5): 2231-2262.

[46]

Dash JR, Pattnaik G, Ghosh G, et al. Protective effect of epicatechin in diabetic-induced peripheral neuropathy: a review[J].J Appl Pharm Sci, 2023, 13(1): 56-63.

[47]

Deng J, Yan F, Tian J, et al. Potential clinical biomarkers and perspectives in diabetic cardiomyopathy[J].Diabetol Metab Syndr, 2023, 15(1): 35.

[48]

Ozorowski M, Wiciński M, Kuźmiński O, et al. The effects of quercetin on vascular endothelium, inflammation, cardiovascular disease and lipid metabolism-a review[J].Nutrients, 2025, 17(9): 1579.

[49]

Wei Z, Jing Z, Pinfang K, et al. Quercetin inhibits pyroptosis in diabetic cardiomyopathy through the Nrf2 pathway[J].J Diabetes Res, 2022, 2022: 9723632.

[50]

He Y, Wang S, Sun H, et al. Naringenin ameliorates myocardial injury in STZ-induced diabetic mice by reducing oxidative stress, inflammation and apoptosis via regulating the Nrf2 and nf-κb signaling pathways[J].Front Cardiovasc Med, 2022, 9: 946766.

[51]

刘丹, 苗加伟, 谭子豪, 等. 柚皮苷对心血管疾病的药理作用研究进展[J].中国临床药理学与治疗学, 2025, 30(2): 272-281.

[52]

Huang R, Shi Z, Chen L, et al. Rutin alleviates diabetic cardiomyopathy and improves cardiac function in diabetic apoeknockout mice[J].Eur J Pharmacol, 2017, 814: 151-160.

[53]

Jia Q, Yang R, Mehmood S, et al. Epigallocatechin-3-gallate attenuates myocardial fibrosis in diabetic rats by activating autophagy[J].Exp Biol Med, 2022, 24(17): 1591-1600.

[54]

Reis A, Rocha S, Dias IH, et al. Type 2 diabetes mellitus alters the cargo of (poly) phenol metabolome and the oxidative status in circulating lipoproteins[J].Redox Biol, 2023, 59: 102572.

[55]

Hakami T, Mahmoud MI, de Juan E, et al. Pharmacokinetics of genistein distribution in blood and retinas of diabetic and non-diabetic rats[J].Drug Metab Pharmacokinet, 2021, 39: 100404.

[56]

Taheri Y, Sharifi-Rad J, Antika G, et al. Paving luteolin therapeutic potentialities and agro-food-pharma applications: emphasis on in vivo pharmacological effects and bioavailability traits[J].Oxid Med Cell Longev, 2021, 2021: 1987588.

[57]

Liu L, Barber E, Kellow NJ, et al. Improving quercetin bioavailability: a systematic review and meta-analysis of human intervention studies[J].Food Chem, 2025, 477: 143630.

[58]

Corcoran MP, McKay DL, Blumberg JB.Flavonoid basics: chemistry, sources, mechanisms of action, and safety[J].J Nutr Gerontol Geriatr, 2012, 31(3): 176-189.

[59]

Jucá MM, Cysne Filho FMS, De Almeida JC, et al. Flavonoids: biological activities and therapeutic potential[J].Nat Prod Res, 2020, 34(5): 692-705.

[60]

Vieira-Frez FC, Sehaber-Sierakowski CC, Perles JVCM, et al. Anti- and pro-oxidant effects of quercetin stabilized by microencapsulation on interstitial cells of cajal, nitrergic neurons and M2-like macrophages in the jejunum of diabetic rats[J].Neurotoxicology, 2020, 77: 193-204.

[61]

Ouyang J, Zhu K, Liu Z, et al. Prooxidant effects of epigallocatechin-3-gallate in health benefits and potential adverse effect[J].Oxid Med Cell Longev, 2020, 2020: 9723686.

[62]

Rasheed NOA, Ahmed LA, Abdallah DM, et al. Paradoxical cardiotoxicity of intraperitoneally-injected epigallocatechin gallate preparation in diabetic mice[J].Sci Rep, 2018, 8(1): 7880.

[63]

Jin Y, Arroo R.The protective effects of flavonoids and carotenoids against diabetic complications-a review of in vivo evidence[J].Front Nutr, 2023, 10: 1020950.

[64]

Hu L, Luo Y, Yang J, et al. Botanical flavonoids: efficacy, absorption, metabolism and advanced pharmaceutical technology for improving bioavailability[J].Molecules, 2025, 30(5): 1184.

[65]

Kalita P, Chakrabarti S, Bhattacharjee B, et al. Recent progress in improving delivery, bioavailability and bioactivity of polyphenolic compounds through encapsulation: a comprehensive review[J].Food Chem, 2025, 490: 145087.

[66]

Mao Y, Luo J, Cai Z. Biosynthesis and regulatory mechanisms of plant flavonoids: a review[J].Plants, 2025, 14(12): 1847.

[67]

Reinhardt JK, Craft D, Weng JK. Toward an integrated omics approach for plant biosynthetic pathway discovery in the age of AI[J].Trends Biochem Sci, 2025, 50(4): 311-321.

基金资助

国家自然科学基金青年基金项目(82204042)

国家自然科学基金面上项目(82373622)

山西省科技创新人才团队(青年)项目(202304051001038)

山西省科技合作交流专项项目(区域合作项目)(2022040411022)

国家卫生健康委员会尘肺病重点实验室开放课题(NHC202307)

山西省高等教育“百亿工程”科技引导专项(BYJL067)

AI Summary AI Mindmap
PDF (7171KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉